| 000 | 01449 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515150201.0 | ||
| 264 | 0 | _c20090623 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/ard.2008.094904 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBongartz, T | |
| 245 | 0 | 0 |
_aEtanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cJul 2009 |
||
| 300 |
_a1177-83 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 |
_aNeoplasms _xchemically induced |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aReceptors, Tumor Necrosis Factor |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aWarren, F C | |
| 700 | 1 | _aMines, D | |
| 700 | 1 | _aMatteson, E L | |
| 700 | 1 | _aAbrams, K R | |
| 700 | 1 | _aSutton, A J | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 68 _gno. 7 _gp. 1177-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/ard.2008.094904 _zAvailable from publisher's website |
| 999 |
_c18476495 _d18476495 |
||